/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Maze Therapeutics

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$41.5 -0.006(-0.6%) MAZE at 09 Dec 2025 05:49 PM Biotechnology
Lowest Today 41.37
Highest Today 42.485
Today’s Open 42.15
Prev. Close 41.71
52 Week High 43.29
52 Week Low 6.71
Day’s Range: Low 41.37 High 42.485
52-Week Range: Low 6.71 High 43.29
1 day return -
1 Week return +11.28
1 month return +35.7
3 month return +151.85
6 month return +225.19
1 year return -
3 year return -
5 year return -
10 year return -

Institutional Holdings

Market Status

Strong Buy: 3

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 2007.06 M

PB Ratio 5.2896

PE Ratio 0.0

Enterprise Value 1647.31 M

Total Assets 240.54 M

Volume 421240

Company Financials

Fund house & investment objective

Company Information Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. The company also offers MZE001, a clinical program for the treatment of Pompe disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

Organisation Biotechnology

Employees 125

Industry Biotechnology

CEO Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow